查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1973759

青光眼房水濕化引流裝置市場：按裝置類型、材質、最終用戶和分銷管道分類 - 全球預測 2026-2032

Glaucoma Aqueous Shunt Device Market by Device Type, Material, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，青光眼房水引流裝置市場價值將達到 5.1984 億美元，到 2026 年將成長至 5.5266 億美元，到 2032 年將達到 7.6084 億美元，複合年成長率為 5.59%。

主要市場統計數據
基準年 2025 5.1984億美元
預計年份：2026年 5.5266億美元
預測年份 2032 7.6084億美元
複合年成長率 (%) 5.59%

本書全面概述了影響青光眼治療中房水引流裝置未來的臨床、技術和商業性因素。

本導論部分為基於臨床的青光眼治療中房水引流裝置的探索奠定了基礎，重點在於技術差異及其對治療路徑的影響。在青光眼治療領域，人們越來越需要能夠平衡眼壓控制、病人安全、手術適用性和長期生物相容性的裝置。本報告整合了臨床趨勢、材料科學進展、分銷動態和監管趨勢，為裝置製造商、臨床醫生和投資者提供了一個統一的觀點。

重大變革重新定義了整個醫療保健領域房水分流技術的產品設計、監管策略和分銷方式。

產業格局的變革正在重塑青光眼房水引流管製造商的設計、監管合規和市場准入策略。首先，臨床上對微創和可重複治療效果的需求促使製造商重新評估裝置的幾何形狀和流量控制機制，從而推動材料工程領域的漸進式創新和突破。其次，手術能力和成本效益正成為醫療系統的首要考慮因素，因此，能夠實現可預測的手術時間和高效的術後管理的裝置變得尤為重要。

貿易政策的變化和關稅壓力迫使製造商重新設計其採購、庫存和製造策略，以保護利潤率和供應鏈的連續性。

近期關稅措施和貿易政策轉變的累積效應，正給眼科器械製造商的供應鏈帶來切實的壓力，尤其是那些依賴國際採購的特種聚合物和組件的企業。半成品關稅導致成本上升，擠壓了利潤空間，促使企業重新談判供應商契約，並加速重新評估製造地。為此，許多企業正在審查關鍵投入品的總到岸成本，並透過優先選擇具備本地生產能力和多元化貿易路線的供應商來降低風險。

實際細分分析揭示了設備類型、最終用戶環境、分銷方式和材料選擇如何影響採用趨勢。

關鍵的細分洞察揭示了器械類型、終端用戶環境、分銷管道和材料選擇如何影響臨床應用路徑和商業性重點。按類型分類，器械分為非瓣膜植入（包括Aadi植入、Baerveldt植入和Molteno植入等設計）和瓣膜解決方案（例如Ahmed瓣膜）。這些區分對於外科醫師的偏好、術後管理通訊協定和長期表現預期至關重要。終端使用者細分涵蓋門診手術中心、醫院和專科眼科診所，每個機構的採購流程、病例組成和手術能力預期各不相同，這些因素都會影響產品規格和服務模式。

區域觀點與營運實務：展示醫療保健系統、採購規範和供應鏈如何影響全球市場中的設備部署。

區域趨勢，源自於醫療基礎設施、報銷標準和臨床實踐模式的差異，導致房水分流裝置的營運現狀和應用曲線各不相同。在美洲，成熟的醫院系統和專科診所優先考慮長期療效和安全性的驗證，而門診手術中心則擴大採用能夠縮短手術時間和減輕術後追蹤負擔的裝置。這就催生了對既能體現手術效率又能展現臨床療效的解決方案的需求。在歐洲、中東和非洲，由於監管協調、國家採購架構以及專科醫療服務取得的差異，分流裝置的應用情況更加多樣化。因此，需要製定針對特定區域的監管策略和定價方法。

企業對競爭考察和策略的洞察：揭示創新、夥伴關係和臨床證據如何推動差異化和市場進入成功。

主要企業之間的競爭格局呈現出兩極化：既有擁有成熟臨床經驗的老牌企業，也有專注於材料創新和低成本製造的參與企業。成熟的外科植入製造商通常依靠臨床醫生的認可、全面的培訓計畫以及提供短期臨床支援的分銷網路來競爭。而新參與企業則力求透過創新的材料方法、模組化或微創設計以及針對門診手術中心和診所的定向商業性提案來取代現有產品，並展現出卓越的運營能力。

為確保永續的競爭優勢，提出整合臨床證據、健全的採購和客製化商業策略的實用建議。

產業領導者應採取平衡策略，將目標明確的臨床證據的獲取與切實可行的供應鏈最佳化和客製化的商業化模式相結合。優先進行針對醫院和門診手術中心關鍵運作終點（例如手術時間、併發症發生率和術後資源利用率）的臨床研究，同時也要關注影響臨床醫師決策的以病人為中心的結局指標。此外，還應投資於供應商多元化，並對替代聚合物來源進行認證，以降低關稅風險和對單一供應商的依賴風險。

採用穩健的混合調查方法，結合專家訪談、臨床文獻回顧和供應鏈分析，確保獲得基於證據的見解。

本調查方法採用混合方法，結合了對外科醫生、採購負責人和行業高管的定性訪談，以及對同行評審的臨床文獻、監管申報文件和供應商文件的詳細審查。主要訪談著重於醫療設備在真實臨床環境中的表現、不同醫療環境下的應用促進因素以及採購決策標準。次要研究則整合了臨床結果數據、醫療設備標籤資訊和監管摘要，以及與分流器製造中常用聚合物相關的材料科學文獻。

為了推動產品普及，需要進行果斷的整合，強調以證據為基礎的產品策略、供應鏈彈性、以及通路特定的商業化。

總之，腦積水引流裝置市場正處於轉折點，其促進因素包括不斷變化的臨床預期、材料技術的創新以及影響採購和分銷的地緣政治壓力。成功需要多管齊下的策略，該策略需協調設備設計選擇與終端用戶的操作需求，預見監管和關稅方面的挑戰，並制定針對醫院、門診手術中心和專科診所具體特點的分銷方案。那些採取實證方法、投資於供應鏈韌性並制定符合各醫療機構實際情況的商業化策略的公司，將更有利於最大限度地提升臨床和商業性價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 青光眼房水引流裝置市場：依裝置類型分類

  • 無閥型
    • Ardi植入
    • 裸帶植入
    • 莫爾特諾植入
  • 帶閥門

第9章 青光眼房水引流裝置市場：依材料分類

  • 聚二甲基矽氧烷
  • 聚丙烯
  • 矽酮

第10章 青光眼房水引流裝置市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 眼科診所

第11章 青光眼房水引流裝置市場：依通路分類

  • 直銷
  • 第三方經銷商

第12章 青光眼房水引流裝置市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 青光眼房水引流裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 青光眼房水引流裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國青光眼房水引流裝置市場

第16章：中國青光眼房水濕化引流裝置市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alcon Inc.
  • Bausch+Lomb Corporation
  • Carl Zeiss Meditec AG
  • Glaukos Corporation
  • iSTAR Medical SA
  • Ivantis, Inc.
  • Johnson & Johnson Vision Care, Inc.
  • MicroSurgical Technology, Inc.
  • New World Medical, Inc.
  • Nova Eye Medical Limited
  • Ocular Therapeutix, Inc.
  • OPTI Medical Systems, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • STAAR Surgical Company
Product Code: MRR-546E6FBB35F9

The Glaucoma Aqueous Shunt Device Market was valued at USD 519.84 million in 2025 and is projected to grow to USD 552.66 million in 2026, with a CAGR of 5.59%, reaching USD 760.84 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 519.84 million
Estimated Year [2026] USD 552.66 million
Forecast Year [2032] USD 760.84 million
CAGR (%) 5.59%

A comprehensive introduction framing clinical, technological, and commercial considerations shaping the future of aqueous shunt devices in glaucoma care

The introduction sets the stage for a focused, clinically grounded exploration of aqueous shunt devices used in glaucoma care, emphasizing technological differentiation and care pathway impact. Glaucoma management increasingly requires devices that balance intraocular pressure control with patient safety, surgical adaptability, and long-term biocompatibility. This report synthesizes clinical trends, material science advances, distribution dynamics, and regulatory developments to provide a coherent perspective for device manufacturers, clinicians, and investors.

Recent years have seen intensified scrutiny of device performance across diverse clinical settings, ranging from tertiary hospitals to high-volume ambulatory surgical centers and specialized ophthalmic clinics. As such, the conversation around aqueous shunts is shifting from purely technical efficacy to a broader evaluation that includes operational efficiency, cost of care, and the ability to integrate into evolving glaucoma treatment algorithms. This introduction frames the subsequent sections by highlighting how device type, end user environment, distribution choices, and material composition collectively influence adoption pathways and commercial strategies.

Key transformative shifts redefining product design, regulatory strategy, and distribution approaches for aqueous shunt technologies across care settings

Transformative shifts in the landscape are reshaping how manufacturers approach design, regulatory engagement, and market entry for glaucoma aqueous shunts. First, the clinical imperative for minimally invasive and reproducible outcomes is driving a reevaluation of device geometry and flow control mechanisms, encouraging incremental innovation as well as step-changes in materials engineering. Second, health systems are prioritizing surgical throughput and cost efficiency, which elevates the importance of devices that facilitate predictable operative times and streamlined postoperative management.

At the same time, regulatory frameworks have become more stringent around long-term safety data and post-market surveillance, prompting developers to invest earlier in real-world evidence generation and structured registries. Distribution models are also evolving, with manufacturers exploring direct-sales relationships for complex hospital accounts while leveraging third-party distributors to expand reach into ambulatory surgical centers and specialty clinics. Finally, supply-chain resilience and supplier qualification have gained strategic importance, encouraging a dual focus on supplier diversification and tighter quality controls to mitigate disruptions and ensure consistent material performance.

How trade policy shifts and tariff pressures compel manufacturers to redesign sourcing, inventory, and manufacturing strategies to protect margins and supply continuity

The cumulative impact of recent tariff actions and trade policy shifts has created tangible pressure points across the supply chain for ophthalmic device manufacturers, particularly those reliant on specialized polymers and components sourced internationally. Tariff-driven cost increases on intermediate goods can compress margins, prompt renegotiation of supplier contracts, and accelerate reconsideration of manufacturing footprints. In response, many organizations are reassessing the total landed cost of key inputs, prioritizing suppliers with local manufacturing capabilities or diversified trade corridors to reduce exposure.

Moreover, tariff volatility influences inventory policies and capital allocation; companies may increase buffer inventories for critical components or invest in dual-sourcing strategies to maintain continuity of supply. These operational choices have knock-on effects for cash flow and working capital, reinforcing the need for integrated procurement and finance planning. Regulatory compliance and customs practices also require greater attention, as misclassification or inadequate documentation can exacerbate tariff burdens. Ultimately, the policy landscape is shifting competitive dynamics by advantaging firms that proactively adapt sourcing strategies, enhance supplier relationships, and invest in manufacturing flexibility within lower-risk jurisdictions.

Actionable segmentation intelligence revealing how device type, end-user environments, distribution approaches, and material choices drive adoption dynamics

Key segmentation insights illuminate how device type, end-user environment, distribution channel, and material selection each shape clinical adoption pathways and commercial priorities. Devices categorized by type split into non-valved implants, which include designs such as Aadi implant, Baerveldt implant, and Molteno implant, and valved solutions represented by options like the Ahmed valve; these distinctions matter for surgeon preference, postoperative management protocols, and long-term performance expectations. End-user segmentation spans ambulatory surgical centers, hospitals, and specialized ophthalmic clinics, each presenting distinct procurement processes, case-mix considerations, and procedural throughput expectations that influence product specification and service models.

Distribution dynamics are also consequential: manufacturers leveraging direct-sales models often secure deep clinical engagement and provide tailored training for hospital accounts, whereas third-party distributors can extend reach into distributed ambulatory centers and independent clinics but may require streamlined product portfolios and robust collateral. Material segmentation that differentiates polydimethylsiloxane, polypropylene, and silicone underlines how biocompatibility, flexibility, and manufacturing scalability affect both device performance and regulatory pathways. When these segmentation dimensions are considered together, they reveal actionable vectors for targeted clinical studies, value proposition refinement, and channel-specific commercialization tactics.

Regional perspectives and operational realities showing how healthcare systems, procurement norms, and supply chains shape device adoption across global markets

Regional dynamics create different operational realities and adoption curves for aqueous shunt devices, driven by healthcare infrastructure, reimbursement norms, and clinical practice patterns. In the Americas, established hospital systems and specialty clinics prioritize evidence of long-term efficacy and safety, while ambulatory surgical centers increasingly adopt devices that reduce operative time and postoperative follow-up burden; this creates demand for solutions that can demonstrate procedural efficiency alongside clinical outcomes. Europe, the Middle East, and Africa present a varied landscape where regulatory harmonization, national procurement frameworks, and differing levels of access to subspecialty care produce a mosaic of adoption scenarios, requiring regionally tailored regulatory strategies and pricing approaches.

Asia-Pacific markets exhibit rapid uptake in centers of excellence and urban tertiary institutions, accompanied by growing domestic manufacturing capabilities and intense competition on price and service. Across all regions, alignment with local clinical opinion leaders and targeted real-world evidence programs enhances credibility and uptake. Furthermore, regional supply-chain considerations, such as proximity to polymer suppliers and cost implications of import tariffs, will influence choices around local manufacturing, assembly, and inventory deployment to support reliable distribution and timely clinical support.

Competitive and strategic company insights highlighting how innovation, partnerships, and clinical evidence drive differentiation and market entry success

Competitive dynamics among leading companies reflect a mix of legacy players with established clinical footprints and emerging entrants focused on materials innovation or cost-effective manufacturing. Established surgical implant manufacturers often compete on clinician familiarity, comprehensive training programs, and distributor networks that provide near-term clinical support. Newer entrants differentiate through novel material approaches, modular or minimally invasive designs, and targeted commercial propositions for ambulatory surgical centers and outpatient clinics, seeking to displace legacy devices by demonstrating operational advantages.

Strategic partnerships and acquisitions remain a prominent route to accelerate capability development, whether that involves integrating advanced polymer science, securing manufacturing scale, or enhancing geographic reach via established distributor relationships. Intellectual property around device geometry, flow-control mechanisms, and proprietary surface treatments is a focal point for competitive positioning. Companies that invest in robust post-market surveillance and high-quality clinical studies strengthen their value proposition with payers and procurement committees, while those that streamline logistics and reduce total cost of care appeal to high-throughput surgical environments.

Practical recommendations for leaders to combine clinical evidence, resilient sourcing, and tailored commercial approaches to secure durable competitive advantage

Industry leaders should pursue a balanced strategy that combines targeted clinical evidence generation with pragmatic supply-chain optimization and tailored commercialization models. Prioritize clinical studies that address operational endpoints important to hospitals and ambulatory surgical centers, such as procedural time, complication rates, and postoperative resource utilization, while also capturing patient-centered outcomes that influence clinician choice. Concurrently, invest in supplier diversification and qualify alternative polymer sources to mitigate tariff exposure and reduce single-supplier risk.

Commercially, align distribution strategies with end-user needs: deploy direct-sales resources for complex hospital accounts where clinical training and procedural support differentiate offerings, and engage third-party distributors to scale presence in ambulatory surgical centers and independent ophthalmic clinics. Emphasize durable materials and standardized manufacturing processes that facilitate regulatory approvals across regions and simplify inventory management. Finally, integrate pricing strategies with value-based narratives that communicate total cost-of-care benefits, and maintain agile cross-functional governance to respond rapidly to policy shifts and evolving clinical guidance.

Robust mixed-methods research methodology integrating expert interviews, clinical literature review, and supply-chain analysis to ensure evidence-based insights

The research methodology employed a mixed-methods approach combining primary qualitative interviews with surgeons, procurement officers, and industry executives, alongside a rigorous review of peer-reviewed clinical literature, regulatory filings, and supplier documentation. Primary interviews focused on real-world device performance, adoption drivers in distinct care settings, and procurement decision criteria. Secondary research synthesized clinical outcomes data, device labeling and regulatory summaries, and material science literature relevant to polymers commonly used in shunt construction.

Analytical frameworks included segmentation mapping across device type, end-user environment, distribution channel, and material selection to generate intersectional insights. Supply-chain analysis incorporated input from manufacturing and procurement specialists to evaluate sourcing risks, tariff exposure, and inventory strategies. Quality assurance of the research process relied on cross-validation between interview findings and published clinical evidence, and methodological limitations were addressed through sensitivity checks around expert interpretation and triangulation of diverse information sources.

A conclusive synthesis emphasizing the need for evidence-driven product strategies, supply resilience, and channel-tailored commercialization to drive adoption

In conclusion, the aqueous shunt landscape is at an inflection point defined by evolving clinical expectations, materials innovation, and geopolitical pressures that affect sourcing and distribution. Success requires a multidimensional strategy that harmonizes device design choices with end-user operational needs, anticipates regulatory and tariff-related challenges, and matches distribution approaches to the dynamics of hospitals, ambulatory surgical centers, and specialty clinics. Companies that adopt an evidence-first approach, invest in supply-chain resilience, and tailor commercialization to the realities of each care setting will be best positioned to capture clinical and commercial value.

Moving from insight to execution involves concrete decisions around clinical program prioritization, supplier qualification, and channel investments. Organizations that act decisively to align R&D roadmaps with demonstrable operational benefits, while preserving flexibility in manufacturing and sourcing, will accelerate adoption and reduce exposure to external shocks. The overarching imperative is to convert the aggregated insights presented here into focused initiatives that enhance patient outcomes and strengthen sustainable commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glaucoma Aqueous Shunt Device Market, by Device Type

  • 8.1. Non Valved
    • 8.1.1. Aadi Implant
    • 8.1.2. Baerveldt Implant
    • 8.1.3. Molteno Implant
  • 8.2. Valved

9. Glaucoma Aqueous Shunt Device Market, by Material

  • 9.1. Polydimethylsiloxane
  • 9.2. Polypropylene
  • 9.3. Silicone

10. Glaucoma Aqueous Shunt Device Market, by End User

  • 10.1. Ambulatory Surgical Center
  • 10.2. Hospital
  • 10.3. Ophthalmic Clinic

11. Glaucoma Aqueous Shunt Device Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Third Party Distributor

12. Glaucoma Aqueous Shunt Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Glaucoma Aqueous Shunt Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Glaucoma Aqueous Shunt Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Glaucoma Aqueous Shunt Device Market

16. China Glaucoma Aqueous Shunt Device Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alcon Inc.
  • 17.6. Bausch + Lomb Corporation
  • 17.7. Carl Zeiss Meditec AG
  • 17.8. Glaukos Corporation
  • 17.9. iSTAR Medical SA
  • 17.10. Ivantis, Inc.
  • 17.11. Johnson & Johnson Vision Care, Inc.
  • 17.12. MicroSurgical Technology, Inc.
  • 17.13. New World Medical, Inc.
  • 17.14. Nova Eye Medical Limited
  • 17.15. Ocular Therapeutix, Inc.
  • 17.16. OPTI Medical Systems, Inc.
  • 17.17. Santen Pharmaceutical Co., Ltd.
  • 17.18. STAAR Surgical Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AADI IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AADI IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AADI IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY BAERVELDT IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY BAERVELDT IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY BAERVELDT IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MOLTENO IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MOLTENO IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MOLTENO IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY VALVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY VALVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY VALVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYDIMETHYLSILOXANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYDIMETHYLSILOXANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYDIMETHYLSILOXANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY OPHTHALMIC CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY OPHTHALMIC CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY OPHTHALMIC CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 105. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 106. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 123. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 124. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 129. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 130. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)